KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $13.1 million.

  • CRISPR Therapeutics AG's Other Accumulated Expenses rose 2588.08% to $13.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.1 million, marking a year-over-year increase of 2588.08%. This contributed to the annual value of $13.1 million for FY2025, which is 2588.08% up from last year.
  • CRISPR Therapeutics AG's Other Accumulated Expenses amounted to $13.1 million in Q4 2025, which was up 2588.08% from $563000.0 recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Other Accumulated Expenses high stood at $13.1 million for Q4 2025, and its period low was $332000.0 during Q3 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Other Accumulated Expenses had a median value of $1.2 million in 2021 and averaged $3.0 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 9725.3% in 2021, then surged by 48331.32% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Accumulated Expenses (Quarter) stood at $1.3 million in 2021, then fell by 7.98% to $1.2 million in 2022, then soared by 341.67% to $5.1 million in 2023, then surged by 102.63% to $10.4 million in 2024, then grew by 25.88% to $13.1 million in 2025.
  • Its Other Accumulated Expenses was $13.1 million in Q4 2025, compared to $563000.0 in Q3 2025 and $604000.0 in Q2 2025.